
Bayer and Orion’s Nubeqa shows off strong overall survival benefit in castration-resistant prostate cancer
pharmafile | January 31, 2020 | News story | Medical Communications, Research and Development | Bayer, orion, pharma
Bayer and Finnish pharma firm Orion Corporation have announced positive new Phase 3 data for their jointly developed oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in adult male patients.
The data showed that the drug, when combined with androgen deprivation therapy (ADT), demonstrated a “significant improvement” in overall survival benefit compared to placebo with ADT.
This benefit bolsters previous data supporting the combo’s efficacy in metastasis-free survival compared to the placebo combo. However, thus far, the combo has not produced mature data on its benefit in overall survival; these data as well as those on additional endpoints were confirmed to be in the pipeline to be presented at an upcoming scientific meeting.
The combo has already secured approval in the US, Brazil and Japan for this indication.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …






